Development of QSAR model for indoyl aryl sulfone derivatives as reverse transcriptase inhibitors | Abstract

Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

ISSN: 0975-413X
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission Systemof respective journal.


Development of QSAR model for indoyl aryl sulfone derivatives as reverse transcriptase inhibitors

Author(s): Laxman M Prajapati, Vijay K Parmar, Manish J Patel, Jimish R Patel

QSAR model development of 39 indoyl aryl sulfones was carried out to predict reverse transcriptase inhibition activity. EC50 for reverse transcriptase binding was taken as biological activity. Physicochemical parameters were calculated using PaDEL descriptor software, version 2.1. Stepwise multiple linear regression analysis was applied to derive QSAR models, which were further evaluated for statistical significance and predictive power by internal and external validation. The best quantitative structure activity relationship model was selected having a correlation coefficient (R2) of 0.835, cross-validated correlation coefficient (Q2) of 0780 and, R2 pred of 0.830. The predictive ability of the selected model was also confirmed by leave one-out cross-validation. The QSAR model indicates that the descriptors (nHBint, SaaNH, MDEO-11 and minaaaC) play an important role in enzyme binding. The information derived from the present study may be useful in the design of more potent substituted indoyl aryl sulfones.


Select your language of interest to view the total content in your interested language

30+ Million Readerbase
SCImago Journal & Country Rank
Google Scholar citation report
Citations : 25868

Der Pharma Chemica received 25868 citations as per Google Scholar report

Der Pharma Chemica peer review process verified at publons
Der Pharma Chemica- Journals on pharmaceutical chemistry